Braingaze

Digitalize diagnosis and treatment for cognitive disorders

Company Details

Cognitive disorders such as ADHD and Alzheimer’s Disease are two of the most debilitating diseases with dementia alone causing US$680b in global economic impact. Braingaze offers a patented, scientifically and clinically validated biomarker-based decision support system for early diagnosis of dementia and Alzheimer’s and a game based digital treatment that improves patients’ cognitive health. Braingaze is working with 25 clinics and hospitals in Europe and has signed a partnership with Ping An Group for China market entry.

注意力缺陷多动症和阿尔茨海默氏病等认知障碍是两大最令人衰弱的疾病,单就全球痴呆疾病所带来的经济影响就超过6040亿欧元。Braingaze开发了经过专利和科学验证的基于生物标志物的决策支持系统,用于早期客观诊断痴呆症和阿尔茨海默氏症;同时还开发了基于手机应用程序的数字治疗游戏,可以改善患者的认知健康。Braingaze与25家欧洲诊所和医院合作,也与平安集团合作以开拓中国市场。

Company People

Hans Supèr

Hans Supèr
CTO & Co-founder at Braingaze

Laszlo Bax

Laszlo Bax
CEO & Founder at Braingaze

Braingaze News

VIEW ALL

You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.